Immunovant Ownership
| IMVT Stock | USD 26.42 1.61 6.49% |
Shares in Circulation | First Issued 2018-12-31 | Previous Quarter 171 M | Current Value 174 M | Avarage Shares Outstanding 105.1 M | Quarterly Volatility 45.3 M |
Immunovant | Build AI portfolio with Immunovant Stock |
Immunovant Stock Ownership Analysis
About 57.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.82. Immunovant had not issued any dividends in recent years. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To learn more about Immunovant call PharmD MD at 917 580 3099 or check out https://immunovant.com.Immunovant Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunovant is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunovant backward and forwards among themselves. Immunovant's institutional investor refers to the entity that pools money to purchase Immunovant's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Seas Capital Lp | 2025-06-30 | 2.3 M | Perceptive Advisors Llc | 2025-06-30 | 2.1 M | Geode Capital Management, Llc | 2025-06-30 | 1.8 M | Woodline Partners Lp | 2025-06-30 | 1.5 M | Stempoint Capital Lp | 2025-06-30 | 1.3 M | Goldman Sachs Group Inc | 2025-06-30 | 1.2 M | Pictet Asset Manangement Sa | 2025-06-30 | 1.2 M | Aberdeen Group Plc | 2025-06-30 | 844.7 K | Norges Bank | 2025-06-30 | 687.7 K | Fmr Inc | 2025-06-30 | 18.6 M | Deep Track Capital, Lp | 2025-06-30 | 9.5 M |
Immunovant Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunovant insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunovant's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunovant insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunovant Outstanding Bonds
Immunovant issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunovant uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunovant bonds can be classified according to their maturity, which is the date when Immunovant has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Immunovant Corporate Filings
| 12th of December 2025 Other Reports | ViewVerify | |
FWP | 11th of December 2025 A written communication used by offering participants to offer securities to the public or to solicit securities transactions. | ViewVerify |
F4 | 3rd of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 21st of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.